Floatz logo

Regorafenib

Mesotheliomas Pleural

Institut BergoniéSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Mesotheliomas Pleural cohort.

Asset / SponsorPhaseRating
Eflornithine
Aminex Therapeutics, Inc.
Phase 1/2CCC
tc-510
TCR2 Therapeutics
Phase 1/2CCC
Ipilimumab
TCR2 Therapeutics
Phase 1/2CCC
Cyclophosphamide
TCR2 Therapeutics
Phase 1/2CCC
Rso-021
RS Oncology LLC
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Regorafenib is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
RegorafenibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →